Vizient Hosts Congressional Briefing on the Complexities of Hospital Financing
'Academic medical centers like UCI Health are training future clinicians while delivering essential care,' said Rep. Min (D-CA). 'However, growing financial pressures, especially around Medicaid reimbursement, threaten their ability to keep their doors open. We need to advance policies that ensure reliable reimbursement and protect access to care for all Californians.'
'As a former therapist and licensed nursing home administrator, I've seen first-hand the essential need for access to quality care,' said Rep. Thompson (R-PA). 'Reliable health systems are necessary for the health and economic well-being of rural communities. I look forward to working with all stakeholders to strengthen quality, lower costs, and increase the availability of care.'
'In neighborhoods across Orange County, hospitals are essential for delivering care, supporting jobs, and keeping our families healthy,' said Rep. Correa (D-CA). 'When hospitals in our district face financial strain, the ripple effects are real and immediate. We need strong, common-sense public policy that ensures hard-working American taxpayers have access to the care they need when they need it.'
Moderated by Michael D. Busch, FACHE, senior vice president, member networks at Vizient, the panel featured key healthcare leaders, including:
Stephanie Daubert, Chief Financial Officer, Nebraska Medicine
Steven M. Fontaine, Chief Executive Officer, Penn Highlands Healthcare
Randolph P. Siwabessy, Senior Vice President & Chief Financial Officer, UCI Health & UC Irvine School of Medicine
Panelists discussed the growing financial instability facing hospitals, particularly given the uncertainty around governmental funding. As noted during the briefing, hospitals are a unique combination of public utility, clinical enterprise, and academic mission, which makes their financing inherently complex. Adjusting one policy can unintentionally unravel other parts due to the system's interconnectedness. Panelists also highlighted rising operating costs, persistent labor shortages, delayed reimbursements, and the widening gap between payment rates and the actual cost of care, especially for Medicaid and Medicare patients.
The panel underscored the need for sustainable policy solutions to protect hospital viability and patient access, highlighting priorities such as stabilizing government reimbursement programs, protecting safety net payments and programs and preserving graduate medical education support.
Learn more about Vizient's advocacy and public policy efforts.
About Vizient, Inc.
Vizient, Inc., the nation's largest provider-driven healthcare performance improvement company, serves more than 65% of the nation's acute care providers, including 97% of the nation's academic medical centers, and more than 35% of the non-acute market. The Vizient contract portfolio represents $140 billion in annual purchasing volume enabling the delivery of cost-effective, high-value care. With its acquisition of Kaufman Hall in 2024, Vizient expanded its advisory services to help providers achieve financial, strategic, clinical and operational excellence. Headquartered in Irving, Texas, Vizient has offices throughout the United States. Learn more at www.vizientinc.com.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
an hour ago
- Business Wire
Veolia Heads a Groundbreaking Wastewater Epidemiological Surveillance Across Europe
PARIS--(BUSINESS WIRE)--Regulatory News: Veolia (PARIS:VIE), the world leader in water technologies, is at the helm of a groundbreaking European epidemiological surveillance program that leverages wastewater as a real-time health indicator. The goal: detect emerging threats early and protect urban populations across the continent. Veolia will oversee the monitoring aspect of this three-year program and will analyze up to 500 wastewater samples collected from European cities in its laboratories in Spain. Each sample will undergo more than 500 in-depth analyses, targeting a wide range of pollutants, viruses, bacteria, and drug residues. This initiative is aligned with the revised European directive on wastewater treatment, which formally embeds epidemiological surveillance as a pillar of public health. It is also part of the European 'One Health' strategy, which will enable the analysis of collective behavior, the assessment of the impact of public policies, and the identification of new threats, while strengthening Europe's health sovereignty. This principle was recently reiterated in the European Strategy for Water Resilience. Estelle Brachlianoff, CEO of Veolia said: 'Being a pioneer means anticipating tomorrow's challenges, and that's exactly what we're doing here, by transforming wastewater into an early warning tool on a European scale. This project is a concrete embodiment of our GreenUp strategic plan: our environmental solutions are also solutions for the health of citizens and the resilience of European territories. We are delighted to be able to bring the Group's expertise in water treatment and environmental health to the European Union, and to pave the way for a more connected, intelligent, and preventive public health system.' The project is led by Veolia, in partnership with the CSIC (Spanish National Research Council), Cetaqua (Veolia Water Technology Center), and the University of Santiago de Compostela. It is based on more than ten years of field experience in wastewater monitoring in Madrid, Barcelona, and Seville, covering nearly a third of the Spanish population. Daniel Tugues, CEO of Veolia Spain, said: 'The Covid-19 pandemic has revealed the untapped potential of wastewater for public health monitoring. This project puts that learning into practice on a large scale. We are very proud that the expertise of our teams is recognized at the European level. Thanks to this project, Spain is at the forefront of a new approach to environmental health, combining scientific rigor, technological innovation, and a commitment to the common good.' ABOUT VEOLIA Veolia group aims to become the benchmark company for ecological transformation. Present on five continents with 215,000 employees, the Group designs and deploys useful, practical solutions for the management of water, waste and energy that are contributing to a radical turnaround of the current situation. Through its three complementary activities, Veolia helps to develop access to resources, to preserve available resources and to renew them. In 2024, the Veolia group provided 111 million inhabitants with drinking water and 98 million with sanitation, produced 42 million megawatt hours of energy and treated 65 million tonnes of waste. Veolia Environnement (Paris Euronext: VIE) achieved consolidated revenue of 44.7 billion euros in 2024.
Medscape
an hour ago
- Medscape
Empaveli Approved for C3G and Primary IC-MPGN
The FDA has approved pegcetacoplan (Empaveli, Apellis Pharmaceuticals, Inc.) for the treatment of C3 glomerulopathy (C3G) or primary immune complex membranoproliferative glomerulonephritis (IC-MPGN) in patients aged 12 years and older. C3G and primary IC-MPGN are rare kidney diseases affecting approximately 5000 people in the US, particularly adolescents or young adults. They often lead to kidney failure requiring dialysis or kidney transplant. In the recently released Phase 3 VALIAN Trial 52-week results, patients receiving pegcetacoplan achieved and maintained a significant reduction in proteinuria over baseline, with a mean urine protein-to-creatinine ratio change at week 26 of -68.1% and at week 52 of -67.2%. In addition, the pegcetacoplan group showed a reduction in estimated glomerular filtration rate levels of -1.2 mL/min/1.73 m2 at week 26 and -3.7 mL/min/1.73 m2 at week 52. The most common adverse reactions were infusion site reactions, pyrexia, nasopharyngitis, influenza, cough, and nausea, according to a company press release. The product will carry a black box warning stating, 'Empaveli, a complement inhibitor, increases the risk of serious infections, especially those caused by encapsulated bacteria, such as Streptococcus pneumoniae, Neisseria meningitidis, and Haemophilus influenzae type B. 'Because of the risk of serious infections caused by encapsulated bacteria, Empaveli is available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS) called the EMPAVELI REMS.' Kathleen Dallessio is the Senior Editor for Diabetes & Endocrinology and Nephrology at Medscape Medical News.
New York Times
6 hours ago
- New York Times
Trump Administration Freezes $108 Million in Funds to Duke University
The Trump administration has frozen $108 million in federal funds for Duke University's medical school and health care system, according to two administration officials, after the government accused the university of 'systemic racial discrimination.' Duke University is the latest high-profile school, from Columbia University to Harvard, that the Trump administration has targeted and stripped of a large amount of federal funding, based on vague accusations that the university abets antisemitism or supports diversity, equity and inclusion programs. The move comes amid a wider pressure campaign from the Trump administration to shift the ideological tilt of American higher education. Robert F. Kennedy Jr., the health secretary, and Linda McMahon, the education secretary, sent a letter to Duke administrators on Monday expressing concerns about 'racial preferences in hiring, student admissions, governance, patient care, and other operations' in the university's health care system. In the letter, the officials accused Duke of violating Title VI of the Civil Rights Act, which prohibits discrimination based on race and nationality in programs receiving federal funding. Mr. Kennedy and Ms. McMahon called on Duke Health, the university's health care system, to review all policies 'for the illegal use of race preferences' and to create a 'Merit and Civil Rights Committee' that would work with the federal government. The $108 million cut could be permanent, if the government concludes the university violated the Civil Rights Act, according to the two administration officials, who spoke on condition of anonymity because they were not authorized to speak publicly. Duke University did not immediately respond to an email request for comment. The university is weighing layoffs amid a budget crunch. It's considering about $350 million in cuts, amounting to roughly 10 percent of its budget. In a video message last month, Duke's president, Vincent E. Price, said the university was trying to sort out proposals from the federal government 'that have quite dire implications for the university.' He added there was 'sadly, no scenario in which Duke can or will avoid incurring substantial losses of funding due to these policy changes.' The university has imposed a hiring freeze and developed buyout plans, but Dr. Price said that Duke would 'likely' resort to layoffs.
